NJ State Employees Deferred Compensation Plan’s Theravance Biopharma TBPH Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-58,142	Closed	-$849K	–	364
2025 Q3	$849K	Hold	58,142	–	–	0.09%	207
2025 Q2	$641K	Hold	58,142	–	–	0.08%	237
2025 Q1	$519K	Hold	58,142	–	–	0.07%	263
2024 Q4	$547K	Hold	58,142	–	–	0.07%	275
2024 Q3	$469K	Hold	58,142	–	–	0.06%	305
2024 Q2	$493K	Hold	58,142	–	–	0.06%	283
2024 Q1	$522K	Hold	58,142	–	–	0.07%	279
2023 Q4	$654K	Hold	58,142	–	–	0.09%	233
2023 Q3	$502K	Hold	58,142	–	–	0.08%	268
2023 Q2	$602K	Hold	58,142	–	–	0.09%	237
2023 Q1	$631K	Hold	58,142	–	–	0.1%	229
2022 Q4	$652K	Hold	58,142	–	–	0.11%	203
2022 Q3	$590K	Hold	58,142	–	–	0.1%	214
2022 Q2	$527K	Hold	58,142	–	–	0.09%	249
2022 Q1	$555K	Hold	58,142	–	–	0.08%	273
2021 Q4	$642K	Hold	58,142	–	–	0.08%	252
2021 Q3	$431K	Hold	58,142	–	–	0.06%	319
2021 Q2	$844K	Hold	58,142	–	–	0.11%	199
2021 Q1	$1.19M	Buy	58,142 +20,000	+52%	+$380K	0.17%	137
2020 Q4	$677K	Hold	38,142	–	–	0.1%	200
2020 Q3	$564K	Hold	38,142	–	–	0.1%	194
2020 Q2	$801K	Hold	38,142	–	–	0.15%	137
2020 Q1	$881K	Hold	38,142	–	–	0.2%	114
2019 Q4	$988K	Hold	38,142	–	–	0.17%	127
2019 Q3	$743K	Buy	38,142 +7,000	+22%	+$141K	0.14%	147
2019 Q2	$508K	Hold	31,142	–	–	0.09%	252
2019 Q1	$706K	Buy	31,142 +2,000	+7%	+$50.7K	0.13%	155
2018 Q4	$746K	Sell	29,142 -5,000	-15%	-$135K	0.16%	141
2018 Q3	$1.11M	Hold	34,142	–	–	0.19%	114
2018 Q2	$774K	Hold	34,142	–	–	0.14%	185
2018 Q1	$828K	Hold	34,142	–	–	0.15%	189
2017 Q4	$952K	Buy	34,142 +10,000	+41%	+$296K	0.16%	162
2017 Q3	$827K	Sell	24,142 -25,142	-51%	-$822K	0.15%	203
2017 Q2	$1.96M	Hold	49,284	–	–	0.37%	67
2017 Q1	$1.81M	Hold	49,284	–	–	0.34%	82
2016 Q4	$1.57M	Hold	49,284	–	–	0.31%	100
2016 Q3	$1.79M	Hold	49,284	–	–	0.37%	76
2016 Q2	$1.12M	Hold	49,284	–	–	0.24%	142
2016 Q1	$1.03M	Hold	49,284	–	–	0.22%	159
2015 Q4	$808K	Hold	49,284	–	–	0.17%	207
2015 Q3	$541K	Buy	49,284 +35,000	+245%	+$446K	0.12%	263
2015 Q2	$186K	Hold	14,284	–	–	0.04%	357
2015 Q1	$248K	Hold	14,284	–	–	0.05%	343
2014 Q4	$214K	Hold	14,284	–	–	0.04%	358
2014 Q3	$330K	Hold	14,284	–	–	0.07%	323
2014 Q2	$456K	Buy	+14,284	New	+$430K	0.09%	305

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's TBPH Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Theravance Biopharma (TBPH) in Q4 2025, closing a stake of 58,142 shares — an estimated $849K sold.

NJ State Employees Deferred Compensation Plan first reported a position in TBPH in Q2 2014 and held it in 46 quarters. The position peaked at $1.96M in Q2 2017. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining Theravance Biopharma position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 58,142 Theravance Biopharma shares in Q4 2025, an estimated $849K.
NJ State Employees Deferred Compensation Plan first reported a position in Theravance Biopharma in Q2 2014 and held it in 46 quarters.
NJ State Employees Deferred Compensation Plan's Theravance Biopharma position peaked at $1.96M in Q2 2017.
169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.